{"nct_id":"NCT05108922","title":"A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)","status":"COMPLETED","status_verified_date":"2024-11","start_date":"2021-11-16","start_date_type":"ACTUAL","primary_completion_date":"2022-09-09","primary_completion_date_type":"ACTUAL","completion_date":"2023-09-19","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["LLY"]}